glp-1 weight loss drugs news today Weight-Loss Could Address a Range of Addictions The current range of weight-loss

GLP-1 2.0: where will the next wave of value come from

This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS

We also present practical implications of these glucose-lowering agents for reducing the risk of adverse cardiovascular events and progressive renal comorbidity in patients with T2D and CVD.

Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration that would exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

In 2024, we also saw unprecedented willingness by large numbers of patients to pay out of pocket, even in European markets, as public coverage of AOMs is still limited, at best, and more often non-existent